Prior Authorization Request Form for larotrectinib (**Vitrakvi**) capsules and oral solution



JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting	provider
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

-01				
Step	Troub complete parent and physician mermanon (produce phint).			
.1	Patient Name:	Physician Name:		
	Address:	Address:	_	
	Sponsor ID#	Phone #:	_	
	Date of Birth:	Secure Fax #:		
Step	Please complete the clinical assessment:			
2	Is this medication being prescribed by or in consultation with a hematologist or oncologist?	□ Yes	□ No	
		Proceed to question 2	STOP	
			Coverage not approved	
	2. For which indication is the requested medication being prescribed?	☐ Solid tumor – proceed to question 3		
		☐ Advanced metastatic non-small cell lung cancer (NSCLC) – proceed to question 5		
		☐ Other – proceed to question 6		
	Is the solid tumor metastatic or would surgical resection result in severe morbidity?	□ Yes	□ No	
		Proceed to question 4	STOP	
			Coverage not approved	
	4. Has the solid tumor progressed despite alternative treatment or there are no satisfactory alternative treatments?	□ Yes	□ No	
		Proceed to question 5	STOP	
			Coverage not approved	
	5. Does the tumor have neurotropic tropomysin receptor kinase (NTRK) gene fusion without a known acquired resistance mutation?	□ Yes	□ No	
		Proceed to question 8	STOP	
			Coverage not approved	
	6. Please provide the diagnosis.			
		Proceed to question 7		
	7. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	□ Yes	□ No	
		Proceed to question 8	STOP	
			Coverage not approved	

Prior Authorization Request Form for larotrectinib (**Vitrakvi**) capsules and oral solution

	8. Is the patient of reproductive age?	☐ Yes Proceed to question 9	☐ No Proceed to question 10
	9. Will the patients (males and females) of reproductive potential use effective contraception during treatment and for at least 1 week after discontinuation?	☐ Yes	□ No
		Proceed to question 10	STOP
_			Coverage not approved
	10. Is the patient a female?	☐ Yes	□ No
		Proceed to question 11	Proceed to question 12
	11. Has it been confirmed that the patient will not breastfeed during treatment and for 1 week after	☐ Yes	□ No
	cessation of treatment?	Proceed to question 12	STOP
			Coverage not approved
	12. Which formulation is being requested?	☐ Capsules - Sign and date below	
		☐ Oral solution - Proceed to question 13	
	13. Does the patient have difficulty swallowing the	☐ Yes	□ No
	capsules?	Sign and date below	STOP
			Coverage not approved
Step	Legrify the above is true to the best of my kn	owledge. Please sign and	date:
Step 3	I certify the above is true to the best of my kn	owledge. Please sign and	date:
			date:
	I certify the above is true to the best of my kn	owledge. Please sign and	
			date: .[08 April 2020]
3			
3	Prescriber Signature		.[08 April 2020]
3 or Inter	Prescriber Signature rnal Use Only ved:	Date	.[08 April 2020]
or Inter Approv	Prescriber Signature rnal Use Only ved:	Date Duration of Approval:	.[08 April 2020]